Evidence map›Paper›PMID 37592261›Full record

ArticleCardiovascular diabetology2023

Association between fingertip-measured advanced glycation end products and cardiovascular events in outpatients with cardiovascular disease.

Tomoya Hirai, Kazuhiro Fujiyoshi, Satoru Yamada, Takuya Matsumoto, Junko Kikuchi, Kohki Ishida, Miwa Ishida, Kyo Shigeta, Taiki Tojo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular diabetology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Tomoya HiraiDivision of Rehabilitation, Department of Clinical Practice and Support, Hiroshima University Hospital, Hiroshima, Japan.
Kazuhiro FujiyoshiDepartment of Cardiovascular Medicine, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, 252-0373, Japan. kazuhiro@med.kitasato-u.ac.jp.
Satoru YamadaDiabetes Center, Kitasato University Kitasato Institute Hospital, Minato-ku, Japan.
Takuya MatsumotoDepartment of Cardiac Rehabilitation, Kitasato University Kitasato Institute Hospital, Minato-Ku, Japan.
Junko KikuchiDepartment of Cardiac Rehabilitation, Kitasato University Kitasato Institute Hospital, Minato-Ku, Japan.
Kohki IshidaDepartment of Cardiovascular Medicine, Kitasato University Kitasato Institute Hospital, Minato-ku, Japan.
Miwa IshidaDepartment of Cardiovascular Medicine, Kitasato University Kitasato Institute Hospital, Minato-ku, Japan.
Kyo ShigetaDepartment of Cardiac Rehabilitation, Kitasato University Kitasato Institute Hospital, Minato-Ku, Japan.
Taiki TojoDepartment of Cardiovascular Medicine, Kitasato University Kitasato Institute Hospital, Minato-ku, Japan.
Kitasato University · JPKitasato Institute Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe accumulation of advanced glycation end products (AGEs) is associated with cardiovascular events in patients with cardiovascular disease (CVD). However, the relationship between the AGEs measured by an AGEs sensor noninvasively at the fingertip and prognosis in patients with CVD remains unclear. Therefore, this study aimed to determine the relationship between AGEs score and prognosis among patients with CVD.

methodsA total of 191 outpatients with CVD were included. AGEs score were measured using an AGEs sensor and the patients were classified into groups by the median value of AGEs score. The incidence of major adverse cardiovascular and cerebrovascular events (MACCE) at 30 months was compared between high- and low-AGEs score groups. In addition, receiver operating characteristic (ROC) curve analysis was used to calculate cutoff value for the AGEs score, which discriminates the occurrence of MACCE. Cox regression analysis was performed to identify the factors associated with the presence of MACCE. MACCE included cardiac death, myocardial infarction, percutaneous coronary intervention, heart failure, and stroke.

resultsAGEs score was normally distributed, with a median value of 0.51. No significant intergroup differences were found in laboratory findings, physical functions, or medications. The high-AGEs score group had a significantly higher incidence of MACCE than the low-AGEs score group (27.1 vs. 10.5%, P = 0.007). A high-AGEs score was a risk factor for MACCE (hazard ratio, 2.638; 95% confidence interval, 1.271-5.471; P = 0.009). After the adjustment for confounders other than 6-min walking distance, the AGEs score remained a factor associated with the occurrence of MACCE. The best cutoff AGEs score for the detection of MACCE was 0.51 (area under the curve, 0.642; P = 0.008; sensitivity, 72.2%; specificity, 54.8%).

conclusionsAGEs score measured at the fingertip in patients with CVD is associated with MACCE. AGEs score, which can be measured noninvasively and easily, may be useful as an assessment for the secondary prevention of CVD in patients with CVD.

Indexed as

Cardiovascular DiseasesHeart FailureMyocardial InfarctionGlycation End Products, AdvancedHumansOutpatientsGlycation End Products, AdvancedAdvanced glycation end productsFingertipMajor adverse cardiac and cerebrovascular eventsNoninvasive examinationOutpatient cardiac rehabilitationSecondary prevention

Identifiers

PMID37592261
PMCPMC10436644
OpenAlexW4385932970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.